Skip to main content

Table 3 Meta-regression and subgroup analyses of pooled hazard ratios for progression-free survival

From: Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis

Subgroup

Meta-regression

Pooled HR of PFS

Heterogeneity

No. of studies

Coefficient

Standard error

T value

P value

Tau2

Adjusted R2

HR (95% CI)

P value

I2

P value

Year

20

0.060

0.228

0.26

0.795

0.182

−8.86%

    

 2011–2014

       

0.56 (0.40–0.77)

<0.001

83.00%

<0.001

 2015–2017

       

0.61 (0.48–0.77)

<0.001

73.60%

<0.001

Sample size

20

0.507

0.197

2.57

0.019

0.122

27.34%

    

 <200

       

0.43 (0.30–0.61)

<0.001

72.10%

<0.001

 ≥200

       

0.73 (0.60–0.89)

0.002

75%

<0.001

Gender (male/female ratio)

20

−0.117

0.228

−0.51

0.614

0.177

−5.64%

    

 <2.5

       

0.66 (0.53–0.82)

<0.001

54.50%

0.025

 ≥2.5

       

0.55 (0.40–0.74)

<0.001

84.70%

<0.001

Mean age

20

0.320

0.264

2.21

0.241

0.156

6.69%

    

 <60

       

0.44 (0.23–0.86)

0.015

89.40%

<0.001

 ≥60

       

0.64 (0.53–0.78)

<0.001

69.70%

<0.001

Country

20

0.168

0.301

0.56

0.584

0.173

−3.31%

    

 the USA, Europe

       

0.60 (0.49–0.74)

<0.001

81.40%

<0.001

 Asia

       

0.51 (0.31–0.83)

0.006

39.50%

0.158

ECOG PS (grade 0%)

20

0.036

0.133

0.27

0.79

0.182

−8.59%

    

 <0.5

       

0.35 (0.14–0.89)

0.028

87.20%

<0.001

 ≥0.5

       

0.64 (0.52–0.79)

<0.001

71.90%

<0.001

MSKCC score (favorable%)

20

0.231

0.111

2.08

0.052

0.123

26.74%

    

 <0.25

       

0.43 (0.21–0.87)

0.019

76%

0.002

 ≥0.25

       

0.86 (0.73–1.02)

0.076

40.30%

0.137

Histology (clear cell%)

20

−0.139

0.126

−1.11

0.283

0.166

1.11%

    

 <0.9

       

0.53 (0.39–0.71)

<0.001

29.30%

0.226

 ≥0.9

       

0.51 (0.33–0.79)

0.002

87.90%

<0.001

Prior nephrectomy (%)

20

−0.162

0.129

−1.25

0.226

0.166

1.16%

    

 <0.9

       

0.52 (0.40–0.67)

0.296

17.50%

<0.001

 ≥0.9

       

0.52 (0.33–0.81)

<0.001

89.30%

0.005

No. of disease sites (1%)

20

−0.253

0.139

−1.81

0.086

0.144

13.81%

    

 <0.2

       

0.41 (0.28–0.60)

<0.001

62.40%

0.047

 ≥0.2

       

0.52 (0.37–0.74)

<0.001

0

0.594

Type of analysis

20

−0.030

0.231

−0.13

0.898

0.182

−8.91%

    

 Univariate

       

0.59 (0.42–0.82)

0.002

82.70%

<0.001

 Multivariate

       

0.58 (0.46–0.75)

<0.001

74.50%

<0.001

Study design

20

0.343

0.257

1.34

0.198

0.157

6.32%

    

 Retrospective

       

0.54 (0.44–0.67)

<0.001

74.90%

<0.001

 Prospective

       

0.77 (0.53–1.12)

0.175

76.20%

0.006

Type of TKIs

20

−0.073

0.114

−0.64

0.942

0.178

−10.49%

    

 Axitinib

       

0.70 (0.48–1.03)

0.07

80.90%

0.001

 Sorafenib

       

0.86 (0.65–1.13)

0.277

0

0.339

 Sunitinib

       

0.47 (0.34–0.64)

<0.001

77.90%

<0.001

 Pazopanib

       

0.79 (0.66–0.94)

0.010

0

1.000

  1. No. number, HR hazard ratio, PFS progression-free survival, ECOG PS Eastern Cooperative Oncology Group performance status, MSKCC score Memorial Sloan Kettering Cancer Center score
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us